Publication | Closed Access

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

Autoimmune DiseaseHealthy SubjectsMedicineImmunologyClinical DermatologyPharmacotherapyDermatologyAnti-il-23 MabImmunotherapyPsoriatic ArthritisModerate-to-severe Psoriasis